<http://webisa.webdatacommons.org/prov/303447446>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/365256568> .
<http://webisa.webdatacommons.org/365256568>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/prov#Entity> .
<http://webisa.webdatacommons.org/365256568>	<http://www.w3.org/ns/prov#wasQuotedFrom>	<biospectrumasia.com> .
<http://webisa.webdatacommons.org/prov/54406692>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/365256568> .
<http://webisa.webdatacommons.org/365256568>	<http://www.w3.org/ns/prov#value>	"Mr Geoffrey Kempler, Prana's chairman and CEO, said, Assuming we achieve the positive results we are hoping for in Reach2HD, we plan to meet with the US regulator, the Food and Drug Administration, and other regulatory agencies to discuss the next steps in the clinical development of PBT2 for the treatment of Huntington disease." .